Award

NIH Reporter #4R01CA287114-03

Rewiring T cell exhaustion with immune checkpoint blockade therapy

Recipient

Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States

Award Amount

$2,024,989.00

Ceiling

$2,024,989.00

Awarded

July 20, 2026

Identifier

4R01CA287114-03

This NIH-funded project focuses on enhancing immune checkpoint blockade therapy for melanoma by targeting PSGL-1 to improve T cell responses and patient outcomes.

Description

The project aims to determine whether promoting the development and maintenance of CD8+ T cells can enhance responses to PD-1 immune checkpoint blockade (ICB) therapy by targeting PSGL-1. It investigates the role of T cell subsets, including TSC and TPEX, in anti-tumor responses and explores PSGL-1 blockade as a potential immunotherapy.

View original record